Noxopharm has a portfolio of clinical and preclinical assets relevant to a wide range of diseases, from cancer to numerous inflammatory conditions.

The company is also developing a technology to reduce the side effects and manufacturing costs of mRNA vaccines.

These assets are in various stages of development, and have the potential to complement existing drug portfolios, or to add new markets for companies looking to expand their operations and reach.

One of the core strengths of the Noxopharm team is the focus on external collaborations, whether with research, supply chain or commercial partners.

For information on partnerships, collaboration opportunities and general licencing enquiries for Noxopharm, please email us at: